The SAFE Prospective Registry
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Ostrava
About this trial
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Eligibility criteria
Qualifiers
Atrial fibrillation (Afib); (paroxysmal, persistent)
Patients indicated for catheter ablation and/or electrical cardioversion
Signed informed consent
Disqualifiers
Longstanding or permanent atrial fibrillation
Severe mitral regurgitation
Heart failure with a permanently reduced ejection fraction
Cerebral ischaemic stroke in < 3 months
Trial design
Treatments tested in this trial
- Catheter ablation and/or electrical cardioversion
Treatment groups
60 Participants
are divided into 1 treatment groupLocations
1University Hospital Ostrava70852, OstravaMoravian-Silesian Region, Czechia
Sponsors and collaborators
University Hospital Ostrava
Lead sponsor
Source ClinicalTrials.gov